(Q50634143)

17 March 2018

meta-analysis

0 references

title

A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. (English)

1 reference

17 March 2018

1 reference

Marchetti A

1

1 reference

17 March 2018

LaPensee K

series ordinal

2

1 reference

17 March 2018

An P

series ordinal

3

1 reference

17 March 2018

publication date

1 July 1998

1 reference

17 March 2018

published in

Clinical Therapeutics

1 reference

17 March 2018

volume

20

1 reference

17 March 2018

issue

4

1 reference

17 March 2018

page(s)

851-869

1 reference

17 March 2018

cites work

Treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Therapeutic progress. II: Treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

The annual cost of psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Tazarotene--first of a new generation of receptor-selective retinoids.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

A double-blind, placebo-controlled trial of topical I,25-dihydroxycholecalciferol in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

A double-blind study of topical 1 alpha,25-dihydroxyvitamin D3 in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Calcitriol (1 alpha,25-dihydroxyvitamin D3) ointment in psoriasis, a safety tolerance and efficacy multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Clobetasol propionate ointment once daily versus fluocinonide ointment three times daily in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Meta-analysis for combining Bayesian probabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Rank-order stability analysis (ROSA): testing pharmacoeconomic data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980146-X

7 January 2021

10.1016/S0149-2918(98)80146-X

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018